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ABSTRACT: Introduction: Universally established comprehensive
clinical bulbar scales objectively assessing disease progression
in amyotrophic lateral sclerosis (ALS) are currently lacking. The
goal of this working group project is to design a best practice set
of provisional bulbar ALS guidelines, available for immediate
implementation within all ALS clinics. Methods: ALS specialists
across multiple related disciplines participated in a series of clini-
cal bulbar symposia, intending to identify and summarize the cur-
rently accepted best practices for the assessment and
management of bulbar dysfunction in ALS Results: Summary
group recommendations for individual speech, Augmentative and
Alternative Communication (AAC), and swallowing sections were
achieved, focusing on the optimal proposed level of care within
each domain. Discussion: We have identified specific clinical
recommendations for each of the 3 domains of bulbar functioning,
available for incorporation within all ALS clinics. Future directions
will be to establish a formal set of bulbar guidelines through a
methodological and evidence-based approach.
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Bulbar dysfunction in amyotrophic lateral sclerosis
(ALS) significantly contributes to reductions in qual-
ity of life, social withdrawal, malnutrition, dehydra-
tion, aspiration pneumonia, and early mortality. A
globally recognized working metric, incorporating
reliable clinical assessment scales to monitor bulbar
disease progression in ALS, has yet to be achieved.
Previous attempts aimed at achieving this metric
have fallen short of a satisfactory and comprehensive
protocol.1–5 The Northeast ALS (NEALS) bulbar
subcommittee has recently completed a bulbar prac-
tice survey regarding current practice patterns within
participating sites, which identified significant incon-
sistencies involving the assessment and management
of bulbar dysfunction in ALS.6 These survey results
revealed an urgent need to design and incorporate a
best practice set of provisional guidelines, intended
to comprehensively assess and monitor bulbar dys-
function across clinical sites. In an attempt to
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address this need, the NEALS bulbar subcommittee
recently convened to generate a provisional working
group set of best practice guidelines, as established
through expert standard of care consensus. Our
expected goals are to: (1) Standardize bulbar data
collection across all sites, which will assist in the
acquisition of patient data; (2) Develop guidelines
for the timing of referrals and follow-up evaluations
of speech, augmentative and alternative communica-
tion (AAC), and swallowing; and (3) Propose com-
mon data elements for standardized data collection
of speech, AAC, and swallowing assessments. The
temporal feasibility of implementing these guidelines
within the clinic setting was a critical concern,
emphasizing the required time and ease of adminis-
tration, given the amount of clinical testing ALS
patients routinely undergo from the multiple health
related disciplines during each clinic visit. A prag-
matic approach was, therefore, underscored.
METHODS
Several designated ALS bulbar symposia recently con-
vened to establish consensus summary recommendations
for the assessment of bulbar dysfunction, specifically
related to the domains of speech, AAC, and swallowing.
In attendance were ALS specialists across multiple disci-
plines, including clinical neurology, biostatistics, and
speech-language pathology (SLP) representing the
United States, Canada, and Italy, thereby providing an
expansive range of bulbar expertise from an experienced
clinical perspective. This consensus group worked to
establish provisional guidelines, focusing on speech and
swallowing impairments. The focus of the speech group
was to (1) provide guidance concerning the timing of
patient referrals for a speech and AAC evaluation and
(2) propose common data elements of a clinical speech
exam that are feasible to administer in a busy ALS clinical
setting. The working goal of the swallowing group was to
develop a pragmatic, triage-based clinical pathway to
guide screening, assessment, and management of dys-
phagia in patients with ALS. These symposium sessions
were organized into separate speech, AAC and swallow-
ing sections, resulting in working group summary guide-
lines within each section that ultimately underwent a
comprehensive review by the entire committee.
RESULTS
Speech Section: Clinical Speech Evaluation. The
speech section focused on the establishment of impor-
tant supplementary metrics of related systems and func-
tions, with subsequent system and subsystem analysis:
forced vital capacity/slow vital capacity (FVC/SVC), ALS
Functional Rating Scale Revised (ALSFRS-R), pseudobul-
bar affect (PBA), dysphagia,medications, and cognition.
Guidance regarding Speech referrals. The speech
section recommended SLP speech evaluations at the
initial clinic visit and recommended that all clinic
visits should gather routine clinical information as
listed in Figure 1. Follow-up speech assessments are
suggested as an integral component of each ALS
clinic visit, although frequency and visit duration
may vary depending on multiple factors including
patient needs, SLP availability, physician recommen-
dations, and clinic resources. All patients who pre-
sent with an oral motor exam atypical for bulbar
ALS (i.e., asymmetrical tongue or pharyngeal weak-
ness, oral/throat pain, raspy voice, or swallow diffi-
culties preceding speech impairment) should
undergo an otolaryngology evaluation to rule out
alternative causes.
Common data elements of clinical speech examination.
The common elements of the speech examination are
listed in Figure 1. The Center for Neurologic Study-
Bulbar Function Scale (CNS-BFS), a recently validated
patient reported outcome measure7 that has demon-
strated clinical utility,8 may also include a family mem-
ber or caregiver for guidance to more completely assess
the communication status of the patient. The speech
assessment should include a spontaneous speech sam-
ple and the reading of a short paragraph, such as the
Bamboo9 or Rainbow Passage10 (only for fluent English
speakers and readers; in non-English speakers/readers
another short paragraph should be selected based upon
the patient’s native language). These samples will allow
clinician-based ratings of dysarthria severity (0 = normal,
4 = severe), speaking rate (words per minute), and
involvement of 1 or more of the 4 speech subsystems
(respiratory, phonatory, articulatory, and resonatory).
Clinician based ratings of speech should be supplemen-
ted with objective testing of the involved individual
speech subsystems (Fig. 2). The estimated time nec-
essary to perform the entire speech assessment is
8 to10 min.
AAC Section: Clinical Communication Evaluation. The
AAC section defined the scope of augmentative com-
munication options, identifying the optimal timing
of an evaluation and stressed a proactive approach.
It also focused upon minimizing the patient energy
expenditure while maximizing their collaborative
engagement. Guidance on when to refer for speech
and AAC evaluations, and frequency of follow-up,
was established. Understanding that speech can rap-
idly deteriorate, patient education with AAC expo-
sure and training is critical during the early stages of
disease progression, even before the onset of overt
bulbar symptoms. The AAC evaluation should, there-
fore, be recommended at the time of diagnosis,
regardless of whether speech impairment exists. The
initial screening conducted in the clinic can intro-
duce the AAC concepts to patients and families early
in the disease course, with the implementation of
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technology options at a later date, as appropriate
(Fig. 3). Patient and family counseling regarding the
broader definition of augmentative communication
should also be initiated early, emphasizing the focus
upon broad support of communication through
speaking, writing, texting and/or computer interfac-
ing in the event of ineffective speech.
Guidance regarding AAC referrals. The AAC
section agreed that the initial clinic visit was identi-
fied as the time to arrange referral to an SLP for an
AAC evaluation, which is intended to be an ongoing,
dynamic collaboration between the patient, physi-
cian, and SLP, and not limited to specific technology
selection. The purpose of each evaluation is to iden-
tify and implement strategies to preserve communi-
cation, and to compensate for reduced ability to
communicate effectively.
Swallowing Section: Clinical Swallow Evaluation. The
group initially identified existing barriers or chal-
lenges within ALS centers, including: (1) timing of
referral to SLP services, (2) inconsistencies in the
assessment and management practices for dysphagia,
and (3) specific timing of subsequent swallow inter-
ventions. It was recommended that the SLP clinical
swallowing screen should include objective testing in
each of the following 5 domains: (1) patient-
reported outcomes; (2) dietary intake; (3) pulmonary
function and airway defense physiologic capacity;
(4) bulbar function; and (5) a dysphagia/aspiration
screen.
Guidance regarding Swallowing referrals. SLP clini-
cal swallow referrals should be established early in
the disease course. Table 1 provides an overview of
the importance in gathering clinical information
across each of the above domains, as well as the sup-
porting evidence within the ALS population for spe-
cific assessment tools. Objective measures allow for
documentation of disease progression on swallowing,
including dysphagia-related symptoms, impact on
quality-of-life and dietary intake. The estimated time
and cost of each of these proposed assessments is as
follows: the Eating Assessment Tool-10 is free of
charge and can be administered to the patient while
in the waiting room, the Iowa Oral Pressure Instru-
ment takes 4 min to perform, the cough peak flow
(CPF) takes roughly 1 min with a device cost of
approximately $45, and the Yale Swallow Protocol is
free of charge, requiring 1 min to complete. Objec-
tive measures of voluntary cough airflow have been
noted to demonstrate significant discriminant ability
to detect ALS patients at risk for penetration/
aspiration,1 and have been suggested as a useful
index of airway defense physiologic capacity for
inclusion in the clinical swallowing evaluation by the
SLP.11,12
FIGURE 1. Speech evaluation. The common data elements suggested for inclusion in all clinical evaluations. ALSFRS-R, ALS
Functional Rating Scale-Revised; CNS-BFS, Center for Neurological Study-Bulbar Function Scale.
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Common data elements of clinical swallowing exam.
The distinction between a swallowing screen and a
swallowing assessment was emphasized. The screen
should incorporate a pragmatic approach in manag-
ing a triage flow of care within a busy ALS clinical set-
ting. Specifically, it was recommended that all ALS
patients undergo a swallowing (dysphagia/aspiration)
screen, and those patients presenting with markers of
dysfunction (e.g., failed screening measure) be rou-
ted for a comprehensive swallowing evaluation, which
may also include an instrumental assessment of
swallowing function (e.g., Videofluoroscopic Swallow
Study, VFSS). Although the panel of experts in this
section believed that an instrumental swallowing
exam was important for patients demonstrating a
high risk for aspiration and dysphagia, recent survey
data reveal that only 27% of sites are routinely
administering a VFSS.6 Given the established high
rate of silent aspiration in ALS (i.e., no attempt to
expectorate aspirated material),13 the panel agreed
that direct visualization of swallowing function (safety
and efficiency) and evaluation of the effectiveness of
trialed swallowing maneuvers or strategies will most
reliably be assessed through the use of instrumental
techniques in this patient population. An open dia-
logue concerning the relative role, timing, and utility
of the VFSS in the evaluation and monitoring of swal-
lowing function in individuals with ALS should con-
tinue to evolve, with consideration given to the
availability of specialized and highly trained SLPs in
the ALS multidisciplinary clinic setting, in whose
absence the VFSS may become an essential tool to
accurately determine swallowing risk.
The inclusion of patient and caregiver education was
especially stressed to address: (1) the role of feeding tubes
for supplemental nutrition and hydration, (2) the impor-
tance of proper oral hygiene, emphasizing the association
between poor oral hygiene and aspiration pneumonia in
dysphagia, (3) compensatory swallow strategies and
maneuvers, (4) dietary modifications including food tex-
ture and consistency, and (5) pulmonary hygienewith air-
way clearance and basic life saving techniques.
FIGURE 2. Bulbar case history information, speech evaluation. CNS-BFS, Center for Neurological Study-Bulbar Function Scale
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To summarize, if the patient fails a swallow screen
or presents with other signs or symptoms of bulbar
dysfunction (e.g., patient reported difficulties or
reduced pulmonary clearance), a referral for a thor-
ough swallowing assessment is warranted.
If an SLP is not present in the clinic or does not rou-
tinely see all scheduled clinic patients, the neurologist
should initially examine each patient, focusing on the
following items: the presence of swallowing difficulties,
how food is being prepared, assistance with feeding,
FIGURE 3. Referral goals for AAC evaluation. This triage tool should provide guidance to the speech language pathologist in the ALS
clinic as to the immediate needs to be addressed in an AAC assessment for a person with ALS. It may serve as the basis for defining
the referral content.
Table 1. Clinical swallowing screen: five important assessment domains
Domain Clinical importance Assessment tool* Evidence available
1-Patient-reported outcome Document changes in swallowing-related
symptomatology during disease
progression
Eating Assessment Tool-1015 Patients with EAT-10 scores ≥8 were
3 times more likely to aspirate
(95.5% negative predictive value)14
2-Dietary intake Rating of oral intake (current diet) ALS Severity Scale –Swallowing
Subscale
Published data17







Physiologic index of pulmonary health and
airway protection clearance ability
Forced vital capacity (FVC) FVC <60% predicted suggests
significant clinical pulmonary
involvement
Role in decision-making for feeding tube and
tracheostomy tube placements
Cough testing Patients with peak expiratory flow
(PEF) <4.0 L/s were 3.4 times more
likely to aspirate11
Document pulmonary function changes
during disease progression
4-Bulbar function Anatomical and physiological integrity of
head and neck structures
Oral motor exam (I&I Test) Published data20
Document bulbar functional changes during
disease progression
Lingual function (measured via the
Iowa Oral Performance
Instrument – IOPI)
Maximum tongue pressure <21.0 kPa
was associated with swallowing
dysfunction19
Center for Neurologic Study





If patient fails, recommend comprehensive
swallow evaluation, which may include an
instrumental assessment of swallowing
physiology
Yale Swallow Protocol16 Unpublished data
*Tools reported here are only those with evidence specifically examining the ALS population. Reader is advised that other validated tools may exist within
a domain, although have not specifically been validated for use with the ALS population.
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unintentional weight loss, coughing or choking with
meals, length of time needed to eat, saliva management,
speaking rate, and slurring of speech. Should the clini-
cal exam identify bulbar dysfunction, i.e., findings
reveal tongue weakness, dysarthria with weak cough
(CPF < 240 L/min), and/or compromised respiratory
support (FVC < 60% predicted), then an SLP referral is
warranted for further comprehensive assessment. The
addition of a set of minimally invasive, quick and sensi-
tive (high yield) objective swallowing metrics were
recommended, as presented in Table 1. This highlights
the NEALS Bulbar recommendations for consideration
of 5 important domains related to swallowing function,
and the current suggestions for objective, validated tests
with the inclusion of associated outcomes.
DISCUSSION
The primary intent of this project was to develop
and establish the currently recognized and optimal
bulbar ALS practice parameters, representing an
expert-based standard of care for immediate imple-
mentation within the ALS clinical setting. Ultimately,
through the application of methodological tech-
niques incorporating available systematic online
reviews of each of the summary recommendations, a
formal set of bulbar ALS guidelines will be estab-
lished. These formal guidelines would subsequently
require the inclusion of patient and caregiver partici-
pation, and undergo future modifications as new
evidence-based, clinical bulbar assessment strategies
and applications are identified.
A recognized limitation of this project is the lack of
existing evidence-based support for the currently pro-
posed bulbar measures, a critical direction for future
research. The inclusion of cognitive and behavioral
assessment scales are also omitted due to the time con-
straints within a busy ALS clinic, and the lack of a uni-
versally accepted and validated cognitive scale which
adequately assesses patients with bulbar dysfunction.
The time required to complete these proposed bulbar
assessments may also represent a limitation, yet the esti-
mated combined time for completion of speech and
swallowing assessments should be less than 20min. The
limited existing and validated objective swallow mea-
sures identified to date highlights the critical need to
pursue ongoing clinical research, focusing on the
assessment of bulbar dysfunction as it relates to swallow-
ing dynamics and its impact on clinicalmanagement.
In conclusion, the purpose of this working group pro-
ject is to create a best practice set of bulbar assessment
guidelines, designed for clinical implementation
throughout the broader ALS community. This goal
should most effectively be accomplished through the
establishment of a productive collaboration between
international ALS researchers, clinicians, patients, and
caregivers, specifically focusing on motor speech, swal-
low, and communication assessment. This proposed
ongoing “bulbar dialogue” should hasten the creation
of an evidence-based and validated set of formal bulbar
ALS guidelines, attainable within the foreseeable future.
The authors extend their gratitude to Cytokinetics and the Center
for Neurological Studies (CNS) for their generous financial sup-
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